A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.  This study will evaluate the effects of the use of a program to reduce prescribing of a group of commonly prescribed medications called anticholingerics that may adversely effect cognitive functioning in older adults. THIS STUDY IS ENROLLING BY INVITATION ONLY - ResNet data managers will identify physicians from the medical records of Community Health Network, and these participating physicians' patients will be approached for recruitment.' They may be contacted by phone or during clinic visits upon referral from physician.  Physicians agreeing to participate in the study will be randomized to intervention or usual care in random blocks of two or four and stratified by clinic site. Physician randomization status will determine participants’ study groups. Physicians randomized to usual care will not have access to the intervention. Physicians are not the subjects of the study. The subjects are the patients of the physicians. Physicians will not be aware of how or when their patients are being recruited or for what studies they will be offered.